Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Set to Buy More Chinese Drugs (China)

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca has announced it will join the ranks of drug manufacturers choosing to obtain raw materials and active pharmaceutical ingredients from emerging Asian markets. Over the next three years, the company's Chinese contracts will grow from $10 million to $100 million. AstraZeneca has also announced intentions to enact a similar investment plan in India's drug manufacturing industry. The company's move is part of a larger goal to reduce drug production costs, in an effort to keep business lucrative. The industry's renewed respect for the bottom line comes as the result of fierce generic competition and dwindling global patent protection for brand-name drugs. Still, many companies are daunted by a lack of production safety standards and intellectual property rights in some countries. But the promise of improvements in regulatory conditions are making outsourcing to countries like China and India a hard deal for manufacturers to resist. (Click here for more - May Require Paid Subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts